SLC25A20: Potential Drug Target and Biomarker (G788)

Target Name: SLC25A20

NCBI ID: G788

SLC25A20

SLC25A20: Potential Drug Target and Biomarker

SLC25A20 (Simple Localized Calcium Gradient) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and skeletal muscles. It is a member of the SLC protein family, which includes other biological proteins. Functional proteins in the body. SLC25A20 has multiple functions in vivo, such as participating in cell signaling, cell proliferation, cell differentiation and other processes.

In recent years, scientists have discovered that SLC25A20 plays an important role in certain diseases. For example, in Alzheimer's disease, abnormal expression of SLC25A20 is found in patients' neurons. In addition, SLC25A20 is also related to diseases such as diabetes, obesity, and hypertension. Therefore, SLC25A20 is regarded as a potential drug target (or biomarker).

Application of SLC25A20 in drug screening
As a protein, SLC25A20 can be used as a target for drug screening. Scientists use the expression level of SLC25A20 as a target for drug screening to screen for drugs that can reduce the expression level of SLC25A20. These medications can include anti-inflammatory drugs, antioxidants, insulin sensitizers, and more. Through this approach, scientists have discovered a variety of drugs that can be used to treat a variety of diseases, such as Alzheimer's disease, diabetes, obesity, and more.

Application of SLC25A20 in disease diagnosis
The application of SLC25A20 in disease diagnosis is mainly reflected in tumor diagnosis. The expression level of SLC25A20 can be used as an indicator of calcium ion levels in tumor tissue. By measuring the amount of SLC25A20 in tissue, scientists can determine the concentration of calcium ions in tumor tissue. This method can be used to evaluate the growth rate and treatment effect of tumor tissue, providing an important basis for tumor diagnosis.

Application of SLC25A20 in drug target research
As a protein, SLC25A20 can be studied as a drug target. Scientists use the properties of SLC25A20 to study the interaction between SLC25A20 and drugs to determine the drug's mechanism of action and efficacy. Through this method, scientists can discover the role of SLC25A20 in drug targets and provide important basis for drug design and optimization.

Biological functions and pharmacological significance of SLC25A20
As a protein, SLC25A20 has multiple biological functions in organisms. SLC25A20 can participate in cell signaling and regulate processes such as cell proliferation, cell differentiation and apoptosis. SLC25A20 can also participate in extracellular signal transduction, regulate cell-cell interactions and the absorption of extracellular substances. In addition, SLC25A20 can also participate in cell metabolism, regulating intracellular energy metabolism and cellular homeostasis.

The application of SLC25A20 in drug screening and disease diagnosis provides important theoretical basis and experimental basis for drug research and clinical treatment. Further research on the biological functions and pharmacological significance of SLC25A20 can provide important inspiration and foundation for the development of new drugs.

Protein Name: Solute Carrier Family 25 Member 20

Functions: Mediates the electroneutral exchange of acylcarnitines (O-acyl-(R)-carnitine or L-acylcarnitine) of different acyl chain lengths (ranging from O-acetyl-(R)-carnitine to long-chain O-acyl-(R)-carnitines) with free carnitine ((R)-carnitine or L-carnitine) across the mitochondrial inner membrane, via a ping-pong mechanism (PubMed:12892634, PubMed:18307102) (Probable). Key player in the mitochondrial oxidation pathway, it translocates the fatty acids in the form of acylcarnitines into the mitochondrial matrix, where the carnitine palmitoyltransferase 2 (CPT-2) activates them to undergo fatty acid beta-oxidation (Probable). Catalyzes the unidirectional transport (uniport) of carnitine at lower rates than the antiport (exchange) (PubMed:18307102)

The "SLC25A20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets